Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Brasil Produtos
Farmacêuticos Ltda.
Edifício Olimpia Trade
Av. Dr. Cardoso de Melo, 1.184,
17º andar,
Vila Olimpia- São Paulo-SP,
CEP; 04548-004
Brazil
Phone: +55 11 3568 3400
Fax: +55 11 3568 3440
www.biogenidec.com.br
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across…
As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social…
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal. ANVISA’s…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
Latin America is a rapidly growing market for the global medtech industry, offering significant opportunities. With a population of over 650 million people, the region boasts a large and growing…
Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant’s regional strategy, covering how the firm rides out the region’s economic and political storms, its participation in disease…
Latin America is a crucial region for medtech market leader Medtronic. Home to 20,000 of the company’s 95,000+ global workforce, 12 manufacturing plants, and ten commercial organisations, Medtronic LatAm grew…
In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators…
Renata Mihich, a 25-year DHL veteran, recently took on a new role as Head of LatAm for Italian healthcare logistics specialist BOMI GROUP. At a moment of career transformation, BOMI…
While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here,…
See our Cookie Privacy Policy Here
